News
GlobalData on MSN5d
FDA removes Ixchiq partial pause but tightens vaccine’s use
The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older ...
The Ixchiq vaccine was approved for adults 18 and up at risk of exposure to the virus in 2023, when the CDC had recorded 152 ...
French vaccines developer Valneva announced that the US Food and Drug Administration (FDA) has removed its recommended pause ...
The FDA has removed the recommended pause in the use of Valneva’s chikungunya vaccine Ixchiq in individuals aged 60 years and older.
The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with ...
Ixchiq now has a warning about its use among elderly people with multiple underlying health conditions after postmarketing ...
Valneva SE ( NASDAQ: VALN) said on Thursday that the FDA has lifted its pause on the use of its chikungunya vaccine, Ixchiq, ...
The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ® in individuals 60 years of age and ...
UKHSA confirms first UK cases of Oropouche virus in travellers from Brazil. With flu-like symptoms, experts warn ...
MedPage Today on MSN6d
FDA Lifts Pause on Chikungunya Vaccine in Older Adults, With Revised Labeling
"Based on the available data, and its benefit-risk assessment, FDA has removed the recommended pause in the use of Ixchiq in ...
The U.S. Centers for Disease Control and Prevention is warning travelers about a new virus in China called chikungunya. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback